• Technical lead on a NIAID contract for a non-beta-lactam penicillin-binding protein inhibitor with activity against Gram-negative non-fermenting pathogens like Acinetobacter baumannii. • Supporting clinical programs for beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations. • IV program combines cefepime with taniborbactam (VNRX-5133), the first BLI with direct inhibitory activity against Ambler class A, B, C and D enzymes. • Oral program combines ceftibuten with ledaborbactam etzadroxil (prodrug)• Coordinate external collaborations with Dr. Robert Bonomo and Dr. Krisztina Papp-Wallace at the Cleveland VA and Case Western Reserve University.• Work closely with IHMA surveillance study and whole genome sequence analysis• Author internal and external microbiology and biochemistry reports to support NDA filing with FDA

Project Team Leader for antibacterial drug discovery programs. Develop new projects and give progress reports to local site leadership and Novartis Scientific Advisory Board. Supervise and develop associates. Mentor Novartis postdoctoral fellow (2015-2018) and 12-month King’s College, London intern (2016-2017).• Lead biology subteam for LPS biosynthetic target yielding first known inhibitor• Spearhead platform to develop mass spectrometry assay for bacterial compound accumulation • Coordinated innovative bacterial mass spectrometry imaging project with Penn State University• Initiated and led collaboration on bacterial fatty acid biosynthesis with Stanford University

Project Team Leader and member for antibacterial drug discovery programs. Propose and develop new projects and give progress reports to local site leadership. Supervise and develop associates.• Led international NIBR team for target and tool validation of LPS transport pathway• Characterized the effects of depletion of LPS core sugar kinase WaaP and characterized inhibitors• Supervised bacteriology lab relocation from Cambridge, MA to Emeryville, CA• Directed an External Drug Discovery Collaboration with Aurigene (Indian CRO)

Advisor: Christian R. H. Raetz, M.D.,Ph.D. Department of Biochemistry, Duke University Medical CenterResearch and Roles1) Led Duke's portion of the Gates Grand Challenges in Global Health Initiative project to develop safe live, attenuated Salmonella vaccines by detoxification of its LPS (Overall project led by Roy Curtiss, Ph.D.)2) Supervising scientist for NIH Glue Grant for Lipid MAPS Core K (Duke) to develop standardized lipidomic analysis of human serum and macrophages.

Advisor: Christian R. H. Raetz, M.D.,Ph.D. Department of Biochemistry, Duke University Medical CenterPostdoctoral research on the enzymology of:1) The lipopolysaccharide (LPS) late acyltransferase LpxL from Escherichia coli2) The lipid A 1-phosphatase LpxE involved in the modification of LPS.